invite friends ⋅ share via emailtwitter
support the site ⋅ become a member ⋅ unscramble the egg
free120  nbme24  nbme23  nbme22  nbme21  nbme20  nbme19  nbme18  nbme17  nbme16  nbme15  nbme13 

NBME 21 Answers

nbme21/Block 1/Question#9 (13.1 difficulty score)
A 53-year-old woman who underwent an ...
Breast: antagonist; Uterus: partial agonist🔍

Login to comment/vote.

 +7  upvote downvote
submitted by pparalpha(78),
unscramble the site ⋅ become a member ($36/month)


ehanis:mcM eleitvecs nseogrte rtporece tmldooaur (SERM) tath scta as an snanioagtt on hte teoensgr seoctprer of eht rtsaeb nad acst as an traipla gnaoist on rneegots rpestcore in bnoe nad .teuurs eThr,eefro ↑ rski of learitonemd cnaecr dna ↑ iksR of nierteu araocms

eU:ss RE or PR vitpsoie orstum ea)stb(r

Whole point of administering a SERM after breast cancer is to reduce risk of recurrence. Increased estrogen exposure is associated with increased risk of breast cancer (per FA 2019 p. 636). So you're looking for something that is an estrogen antagonist at the breast, which narrows it down to B and C right off the bat.